Albert Labs a company accelerating access to psychedelic-based medicines for patients with urgent and unmet is expected to commence trading on the CSE under the ticker “ABRT” early in the new year. VANCOUVER, BC, Nov. 29, 2021 /CNW/ – Albert Labs (or the “Company”), today announced that it has received conditional approval for the listing of its common shares on the Canadian Securities Exchange…

Source

Previous articleNuminus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans
Next articleatai Life Sciences Increases its Ownership Position in COMPASS Pathways